Fig. 4.

Summary of the comparative safety of belamaf versus sel + dex before and after MAIC adjustment using all MAIC models. A Hematologic and B non-hematologic adverse events. ^aIncludes the preferred terms thrombocytopenia, platelet count decreased; ^bincludes the preferred terms lymphopenia, lymphocyte count decreased; ^cincludes the preferred terms fatigue and asthenia. OR < 1 favors belamaf; OR < 0.5, risk 50% lower with belamaf. TEAEs highlighted in gray boxes were significantly different. Belamaf, belantamab mafodotin; CI, confidence interval; MAIC, matching adjusted indirect comparison; sel + dex, selinexor plus dexamethasone; TEAE, treatment-related adverse events